Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open-label study.

Authors	Myrthe J van Dijk, Minke A E Rab, Brigitte A van Oirschot, Jennifer Bos, Cleo Derichs, Anita W Rijneveld, Marjon H Cnossen, Erfan Nur, Bart J Biemond, Marije Bartels, Judith J M Jans, Wouter W van Solinge, Roger E G Schutgens, Richard van Wijk, Eduard J van Beers
Journal	American journal of hematology (Am J Hematol) Vol. 97 Issue 7 Pg. E226-E229 (07 2022) ISSN: 1096-8652 [Electronic] United States
PMID	35384026 (Publication Type: Clinical Trial, Phase II, Letter, Research Support, Non-U.S. Gov't)
Chemical References	Piperazines Quinolines mitapivat Pyruvate Kinase
Topics	Anemia, Sickle Cell (drug therapy) Humans Piperazines (adverse effects) Pyruvate Kinase Quinolines (adverse effects) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!